Name: Name:Bibr 1532
Brand: AABLOCKS
SKU: AA00C6C6
Rating: 90 (10 reviews)

Technical Information

Catalog Number: AA00C6C6

Chemical Name: Bibr 1532

CAS Number: 321674-73-1

Molecular Formula: C21H17NO3

Molecular Weight: 331.3646

MDL Number: MFCD11112195

SMILES: O=C(Nc1ccccc1C(=O)O)/C=C(/c1ccc2c(c1)cccc2)\C

Properties

BP: 600.607°C at 760 mmHg

Form: Solid

MP: >173ºC (dec.)

Storage: Keep in dry area;2-8℃;

Complexity: 527

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 0

Defined Bond Stereocenter Count: 1

Formal Charge: 0

Heavy Atom Count: 25

Hydrogen Bond Acceptor Count: 3

Hydrogen Bond Donor Count: 2

Isotope Atom Count: 0

Rotatable Bond Count: 4

Undefined Atom Stereocenter Count: 0

Undefined Bond Stereocenter Count: 0

XLogP3: 5.1

Literature fold

Title: BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL.

Journal: Anti-cancer agents in medicinal chemistry20130901

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters20130801

Title: A new strategy for detection and development of tractable telomerase inhibitors.

Journal: Journal of medicinal chemistry20120426

Title: Screening of telomerase inhibitors.

Journal: Methods in molecular biology (Clifton, N.J.)20070101

Title: Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment.

Journal: Molecular pharmacology20050901

Title: Pascolo E, et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem. 2002 May 3;277(18):15566-72.

Title: El-Daly H, et al. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood. 2005 Feb 15;105(4):1742-9.

Title: Ward RJ, et al. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol. 2005 Sep;68(3):779-86.

Title: A Röth, et al. Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia. Leukemia. 2007 Dec;21(12):2456-62.

Title: Meng E, et al. Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells. Gynecol Oncol. 2012 Mar;124(3):598-605.

321674-73-1 | Bibr 1532